384 related articles for article (PubMed ID: 28448754)
1. CLINICAL EVALUATION OF COST EFFICACY OF DRUGS FOR TREATMENT OF OSTEOPOROSIS: A META-ANALYSIS.
Albert SG; Reddy S
Endocr Pract; 2017 Jul; 23(7):841-856. PubMed ID: 28448754
[TBL] [Abstract][Full Text] [Related]
2. Economic evaluation of four treatment strategies for postmenopausal patients with osteoporosis and a recent fracture in mainland China: a cost-effectiveness analysis.
Tian L; Luo C; Li YF; Wang QY; Qu XL; Yue C; Xu LL; Yang YY; Sheng ZF
Arch Osteoporos; 2023 Jul; 18(1):100. PubMed ID: 37460858
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis.
Jönsson B; Ström O; Eisman JA; Papaioannou A; Siris ES; Tosteson A; Kanis JA
Osteoporos Int; 2011 Mar; 22(3):967-82. PubMed ID: 20936401
[TBL] [Abstract][Full Text] [Related]
4. Time to Benefit of Bisphosphonate Therapy for the Prevention of Fractures Among Postmenopausal Women With Osteoporosis: A Meta-analysis of Randomized Clinical Trials.
Deardorff WJ; Cenzer I; Nguyen B; Lee SJ
JAMA Intern Med; 2022 Jan; 182(1):33-41. PubMed ID: 34807231
[TBL] [Abstract][Full Text] [Related]
5. Comparison of anti-fracture effectiveness of zoledronate, ibandronate and alendronate versus denosumab in a registry-based cohort study.
Everts-Graber J; Bonel H; Lehmann D; Gahl B; Häuselmann H; Studer U; Ziswiler HR; Reichenbach S; Lehmann T
Osteoporos Int; 2023 Nov; 34(11):1961-1973. PubMed ID: 37493978
[TBL] [Abstract][Full Text] [Related]
6. Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis.
Grima DT; Papaioannou A; Thompson MF; Pasquale MK; Adachi JD
Osteoporos Int; 2008 May; 19(5):687-97. PubMed ID: 18008100
[TBL] [Abstract][Full Text] [Related]
7. The clinical effectiveness of denosumab (Prolia®) in patients with hormone-sensitive cancer receiving endocrine therapy, compared to bisphosphonates, selective estrogen receptor modulators (SERM), and placebo: a systematic review and network meta-analysis.
Nicolopoulos K; Moshi MR; Stringer D; Ma N; Jenal M; Vreugdenburg T
Arch Osteoporos; 2023 Jan; 18(1):18. PubMed ID: 36624318
[TBL] [Abstract][Full Text] [Related]
8. The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women.
Hopkins RB; Goeree R; Pullenayegum E; Adachi JD; Papaioannou A; Xie F; Thabane L
BMC Musculoskelet Disord; 2011 Sep; 12():209. PubMed ID: 21943363
[TBL] [Abstract][Full Text] [Related]
9. Real-world effectiveness of osteoporosis therapies for fracture reduction in post-menopausal women.
Yusuf AA; Cummings SR; Watts NB; Feudjo MT; Sprafka JM; Zhou J; Guo H; Balasubramanian A; Cooper C
Arch Osteoporos; 2018 Mar; 13(1):33. PubMed ID: 29564735
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonate alternative regimens for the prevention of osteoporotic fragility fractures: BLAST-OFF, a mixed-methods study.
Sahota O; Narayanasamy M; Bastounis A; Paskins Z; Bishop S; Langley T; Gittoes N; Davis S; Baily A; Holmes M; Leonardi-Bee J
Health Technol Assess; 2024 Apr; 28(21):1-169. PubMed ID: 38634483
[TBL] [Abstract][Full Text] [Related]
11. Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study.
Tutaworn T; Nieves JW; Wang Z; Levin JE; Yoo JE; Lane JM
Osteoporos Int; 2023 Mar; 34(3):573-584. PubMed ID: 36602607
[TBL] [Abstract][Full Text] [Related]
12. Medical treatment of vertebral osteoporosis.
Lippuner K
Eur Spine J; 2003 Oct; 12 Suppl 2(Suppl 2):S132-41. PubMed ID: 13680313
[TBL] [Abstract][Full Text] [Related]
13. The effectiveness of ibandronate in reducing the risk of nonvertebral fractures in women with osteoporosis: systematic review and meta-analysis of observational studies.
Alves C; Mendes D; Penedones A; Oliveira T; Donato A; Batel-Marques F
Int J Clin Pharm; 2024 Apr; 46(2):357-367. PubMed ID: 38112890
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of once-yearly zoledronic acid in Japanese patients with primary osteoporosis: two-year results from a randomized placebo-controlled double-blind study (ZOledroNate treatment in Efficacy to osteoporosis; ZONE study).
Nakamura T; Fukunaga M; Nakano T; Kishimoto H; Ito M; Hagino H; Sone T; Taguchi A; Tanaka S; Ohashi M; Ota Y; Shiraki M
Osteoporos Int; 2017 Jan; 28(1):389-398. PubMed ID: 27631091
[TBL] [Abstract][Full Text] [Related]
15. Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture.
Cadarette SM; Katz JN; Brookhart MA; Stürmer T; Stedman MR; Solomon DH
Ann Intern Med; 2008 May; 148(9):637-46. PubMed ID: 18458276
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.
Ayers C; Kansagara D; Lazur B; Fu R; Kwon A; Harrod C
Ann Intern Med; 2023 Feb; 176(2):182-195. PubMed ID: 36592455
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of buffered soluble alendronate 70 mg effervescent tablet for the treatment of postmenopausal women with osteoporosis in Italy.
Hiligsmann M; Maggi S; Veronese N; Sartori L; Reginster JY
Osteoporos Int; 2021 Mar; 32(3):595-606. PubMed ID: 33443610
[TBL] [Abstract][Full Text] [Related]
18. Hip fracture protection by alendronate treatment in postmenopausal women with osteoporosis: a review of the literature.
Iwamoto J; Sato Y; Takeda T; Matsumoto H
Clin Interv Aging; 2008; 3(3):483-9. PubMed ID: 18982918
[TBL] [Abstract][Full Text] [Related]
19. Parathyroid Hormone and Parathyroid Hormone-Related Protein Analogs in Osteoporosis Therapy.
Leder BZ
Curr Osteoporos Rep; 2017 Apr; 15(2):110-119. PubMed ID: 28303448
[TBL] [Abstract][Full Text] [Related]
20. Fracture rates and economic outcomes in patients with osteoporosis prescribed risedronate gastro-resistant versus other oral bisphosphonates: a claims data analysis.
Thomasius F; Palacios S; Alam A; Boolell M; Vekeman F; Gauthier G
Osteoporos Int; 2022 Jan; 33(1):217-228. PubMed ID: 34490504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]